EXTENDED REPORT

Effect of tumour necrosis factor antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection

J R Peterson¹, F C Hsu¹, P A Simkin¹, M H Wener^1,2

¹ Division of Rheumatology, University of Washington, USA
² Department of Laboratory Medicine, University of Washington, USA

Correspondence to:
Correspondence to:
Dr M H Wener, Department of Laboratory Medicine, Box 357110, UWMC, Seattle, WA 98195, USA;
wener{at}u.washington.edu

Background: Tumour necrosis factor (TNF) antagonists are effective for the treatment of rheumatoid arthritis (RA), but concerns remain about the safety of these agents in the presence of chronic infections, including hepatitis C virus (HCV) infection.

Objective: To examine the influence of treatment with TNF antagonists on levels of HCV viraemia and serum transaminases in patients with RA and HCV.

Methods: In a retrospective survey the course of 16 HCV infected patients with RA who had received the TNF antagonists etanercept or infliximab was analysed. Eight additional patients with RA and HCV were also enrolled into a three month prospective trial of etanercept. Serum concentrations of albumin, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, and HCV were followed.

Results: Viraemia was measured in 22 patients receiving a TNF antagonist at the start of treatment and after 1–34 months (median 9 months follow up). Twenty four patients had serial tests of liver related enzymes and albumin. None of the differences between liver related tests at baseline and at follow up achieved significance (p>0.05). Similarly, the mean HCV measurement at 1–3, 4–6, 7–12, and 13–34 months did not differ significantly from baseline (p>0.05).

Conclusion: In this study, liver related blood tests and HCV viral load measurements did not change substantially. These findings suggest that TNF antagonists merit further study for the treatment of RA in HCV infected patients. Larger and longer term studies are still needed.

Keywords: tumour necrosis factor ; hepatitis C; rheumatoid arthritis; etanercept; infliximab

Abbreviations: ACR, American College of Rheumatology; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C reactive protein; DMARD, disease modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; HCV, hepatitis C virus; LRT, liver related test; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drug; PCR, polymerase chain reaction; PT, prothrombin time; PTT, partial thromboplastin time; RA, rheumatoid arthritis; TNF, tumour necrosis factor

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Shale, M. J. (2009). The implications of anti-tumour necrosis factor therapy for viral infection in patients with inflammatory bowel disease. Br Med Bull 0: ldp036v1-ldp036 [Abstract] [Full Text]  
• Uda, H., Kuhara, M., Nishimoto, N., Saiki, O. (2009). Progression of viraemia during treatment with infliximab in a patient with rheumatoid arthritis and chronic hepatitis C infection. BMJ Case Reports 2009: bcr0420091732-bcr0420091732 [Abstract] [Full Text]  
• Furst, D E, Keystone, E C, Kirkham, B, Fleischmann, R, Mease, P, Breedveld, F C, Smolen, J S, Kalden, J R, Burmester, G R, Braun, J, Emery, P, Winthrop, K, Bresnihan, B, De Benedetti, F, Dorner, T, Gibofsky, A, Schiff, M H, Sieper, J, Singer, N, Van Riel, P L C M, Weinblatt, M E, Weisman, M H (2008). Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 67: iii2-iii25 [Full Text]  
• Furst, D E, Breedveld, F C, Kalden, J R, Smolen, J S, Burmester, G R, Sieper, J, Emery, P, Keystone, E C, Schiff, M H, Mease, P, van Riel, P L C M, Fleischmann, R, Weisman, M H, Weinblatt, M E (2007). Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 66: iii2-iii22 [Full Text]  
• Marotte, H., Fontanges, E., Bailly, F., Zoulim, F., Trepo, C., Miossec, P. (2007). Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus. Rheumatology (Oxford) 46: 97-99 [Abstract] [Full Text]  
• Furst, D E, Breedveld, F C, Kalden, J R, Smolen, J S, Burmester, G R, Emery, P, Keystone, E C, Schiff, M H, van Riel, P L C M, Weinblatt, M E, Weisman, M H (2006). Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum Dis 65: iii2-iii15 [Full Text]  
• Roux, C. H., Brocq, O., Breuil, V., Albert, C., Euller-Ziegler, L. (2006). Safety of anti-TNF-{alpha} therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology (Oxford) 45: 1294-1297 [Abstract] [Full Text]  
• Furst, D E, Breedveld, F C, Kalden, J R, Smolen, J S, Burmester, G R, Bijlsma, J W J, Dougados, M, Emery, P, Keystone, E C, Klareskog, L, Mease, P J (2005). Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis 64: iv2-iv14 [Full Text]  
• Nissen, M. J., Fontanges, E., Allam, Y., Zoulim, F., Trepo, C., Miossec, P. (2005). Rheumatological manifestations of hepatitis C: incidence in a rheumatology and non-rheumatology setting and the effect of methotrexate and interferon. Rheumatology (Oxford) 44: 1016-1020 [Abstract] [Full Text]  
• Ledingham, J., Deighton, C., on behalf of the British Society for Rheumatology, (2005). Update on the British Society for Rheumatology guidelines for prescribing TNF{alpha} blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford) 44: 157-163 [Full Text]  
• Knobler, H., Schattner, A. (2005). TNF-{alpha}, chronic hepatitis C and diabetes: a novel triad. QJM 98: 1-6 [Abstract] [Full Text]  
• Furst, D E, Breedveld, F C, Kalden, J R, Smolen, J S, Burmester, G R, Bijlsma, J W J, Dougados, M, Emery, P, Keystone, E C, Klareskog, L, Mease, P J (2004). Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. Ann Rheum Dis 63: ii2-ii12 [Full Text]  
• Calabrese, L H, Zein, N, Vassilopoulos, D (2004). Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 63: ii18-ii24 [Abstract] [Full Text]